Navigation Links
Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
Date:9/25/2008

PRINCETON, N.J., Sept. 25 /PRNewswire/ -- Data from a 52-week phase 3 study (LEADTM 3) of Novo Nordisk's (NYSE: NVO) liraglutide, a once-daily human GLP-1 analog, were published online today in The Lancet. The study showed that liraglutide, when taken alone, produces statistically significant and sustained improvements in blood sugar control in patients with early type 2 diabetes, as compared with glimepiride, a widely used oral anti-diabetic drug. Moreover, the treatment with liraglutide led to weight loss, reduced systolic blood pressure and lowered rates of hypoglycemia after 52 weeks of treatment.

"Publication of this data in The Lancet means that more physicians will have access to these key results on liraglutide's efficacy as monotherapy in the treatment of type 2 diabetes," said principal study investigator Alan Garber, MD, Professor of Medicine, Biochemistry & Molecular Biology, and Molecular & Cellular Biology Division of Diabetes, Endocrinology & Metabolism, Baylor College of Medicine, Texas. "In addition to effective glycemic control for at least one year, liraglutide treatment also led to a number of other clinical benefits when given to patients early on in the course of their disease."

Type 2 diabetes is a progressive disease. Many treatments are effective early on in the course of the disease but do not maintain their effectiveness. After 52 weeks of treatment, 62% of treatment-naive patients treated with liraglutide 1.8 mg achieved an average reduction in blood sugar below the American Diabetes Association target for HbA1c of less than 7% and maintained this reduction over the 52-week study period.

In addition, patients treated with liraglutide had significant weight loss. A mean weight loss of 2.05+/-
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
4. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
5. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
6. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
7. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
8. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
10. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
11. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... THOUSAND OAKS, Calif., July 30, 2015  Amgen ... for the second quarter of 2015. Key results ... versus the second quarter of 2014 to $5,370 ... primarily by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... YORK, March 28, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... two abstracts on KRX-0401 (perifosine) will be presented at ... for Cancer Research (AACR) to be held in Orlando, ... potentially first-in-class, oral anti-cancer agent that inhibits Akt activation ...
... 28, 2011 Quest Diagnostics Incorporated (NYSE: ... information and services, announced today it has commenced a ... Corporation, for all of the outstanding shares of common ... CRA ), one of the world,s pioneers in genetic ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting 2Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting 3Quest Diagnostics Commences Tender Offer for Acquisition of Celera 2Quest Diagnostics Commences Tender Offer for Acquisition of Celera 3
(Date:7/30/2015)... ... July 30, 2015 , ... ... the latest issue of Inclusive™ magazine, its multimedia publication focused on implant dentistry, ... of the new issue, Volume 6, Issue 2, as well as past issues ...
(Date:7/30/2015)... ... , ... Western University of Health Sciences faculty, students and alumni were a ... sports and humanitarian event in the world this year and the single biggest event ... 25 through August 2, 2015, benefited from the participation of WesternU’s colleges of osteopathic ...
(Date:7/30/2015)... ... , ... On July 23rd Clay Today Online reported the state ... large prison system, which has amassed largely enough throughout the years. Florida is the ... President Obama’s recent reduction of non violent drug offender’s prison sentences, Florida is beginning ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer patients ... designed specifically for the elimination of excess tissue under the chin, referred to ... state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella ...
(Date:7/30/2015)... ... 2015 , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers ... well as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with ... from around the world. , “Like treatment of any other disease or condition, making ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... ATS 2012, SAN FRANCISCO A tiny, resilient metal wire ... relief to patients with severe heterogeneous emphysema, a subtype of ... lungs, according to the results of a multicenter international trial ... a lung volume reduction coil (LVRC), can be easily implanted ...
... Magnetic resonance imaging (MRI) provides an indication of a ... possible through clinical examination, according to a new study ... Women with breast cancer often undergo chemotherapy prior ... this treatment, known as neoadjuvant chemotherapy, are more likely ...
... MAYWOOD, Ill. -- Children born with cleft lip, cleft ... beyond appearance. Patients can face serious airway, feeding, ... psychological challenges, Laura Swibel Rosenthal, MD, of Loyola University ... issue of Otolaryngologic Clinics of North America . ...
... uproar that began last year when the U.S. Preventive Services ... prostate-cancer tests to healthy men continued this week when the ... their guns, stating that a blood test commonly used to ... than good it leads men to receive unnecessary, and ...
... HealthDay Reporter , TUESDAY, May 22 (HealthDay News) ... with earlier development of precancerous colon lesions recommend people ... a younger age than others. "Based on our ... screenings earlier, possibly at age 40, rather than at ...
... News) -- Healthier lifestyles and better disease management led to ... between 1997 and 2006, especially deaths caused by heart ... During that time, deaths from all causes for Americans with ... disease and stroke in this group declined by 40 percent, ...
Cached Medicine News:Health News:Tiny implanted coil improves lung function in patients with severe emphysema 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 3Health News:Breast MRI helps predict chemotherapy's effectiveness 2Health News:Cleft lip/palate cause much more than cosmetic problems 2Health News:Psychological Science explains uproar over prostate-cancer screenings 2Health News:Middle-Aged Diabetics May Need Earlier Colon Checks 2Health News:Middle-Aged Diabetics May Need Earlier Colon Checks 3Health News:U.S. Sees Drop in Deaths Linked to Diabetes 2Health News:U.S. Sees Drop in Deaths Linked to Diabetes 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: